Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients

This study has been completed.
Sponsor:
Information provided by:
Katholieke Universiteit Leuven
ClinicalTrials.gov Identifier:
NCT00411944
First received: December 13, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
  Purpose

An evaluation of the effects of genetically determined variant metabolizing and transporting proteins involved in the disposition of the immunosuppressive drug tacrolimus in renal transplant recipients. In a five year follow-up study tacrolimus dose-corrected exposure changes significantly and the effect(s) of single nucleotide polymorphisms of the CYP3A4/CYP3A5 and MDR1 genes on the latter is assessed in this study.


Condition Phase
Renal Transplantation
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Prospective Study of the Influence of CYP3A4/CYP3A5 and MDR1 Gene Single Nucleotide Polymorphisms on Long-Term Tacrolimus Disposition in Renal Allograft Recipients: a Five Year Follow-up Study Using Abbreviated Concentration-Time Measurements.

Resource links provided by NLM:


Further study details as provided by Katholieke Universiteit Leuven:

Estimated Enrollment: 100
Study Start Date: August 1999
Estimated Study Completion Date: September 2005
Detailed Description:

A 5-year pharmacokinetic follow-up study in 95 renal allograft recipients assessing tacrolimus exposure using repeated abbreviated Area-Under-the-Concentration-time (AUC) curve measurements at regular time points after grafting. The effects of the CYP3A5*1, CYP3A4*1B, MDR1 G2677T/A and C3435T single nucleotide polymorphisms on the evolution of tacrolimus disposition are studied over 5 years in order to clarify the interrelationship between CYP3A5, CYP3A4 and MDR1 genotypes, time-dependent exposure and tacrolimus-related toxicity.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary or secondary single kidney transplantation
  • Age older than 18 yrs

Exclusion Criteria:

  • Combined organ transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00411944

Locations
Belgium
Department of Nephology and Renal Transplantation
Leuven, Belgium, B-3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Principal Investigator: Dirk R Kuypers, MD, PhD Dpt Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00411944     History of Changes
Other Study ID Numbers: TacLTPK
Study First Received: December 13, 2006
Last Updated: December 13, 2006
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP

Keywords provided by Katholieke Universiteit Leuven:
tacrolimus pharmacokinetics
CYP3A4 - CYP3A5
P-glycoprotein
single nucleotide polymorphisms
renal transplantation
calcineurin-inhibitor-associated nephrotoxicity

Additional relevant MeSH terms:
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014